Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma

Inclusion criteria

• 18-80 year of age
• Body weight ≥40 kg
• Diagnosed with asthma ≥12 months
• Received a total daily dose of medium/high dose of ICS for more than 3 months steadily
• At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
• Morning pre-BD FEV1 <80% but ≥35% predicted normal
• Evidence of asthma as documented by reversibility test or change of PEF.
• Documented history of at least 1 asthma exacerbation events within 12 months.
• ACQ-5 score ≥1.5 at screening and on day of randomization

Exclusion criteria

• Pulmonary disease other than asthma.
• History of cancer within 5 years except those cured.
• History of a clinically significant infection within 4 weeks.
• Current smokers or participants with smoking history ≥10 pack-yrs.
• History of chronic alcohol or drug abuse within 12 months.
• Positive Hepatitis B, C or HIV infection.
• Pregnant or breastfeeding.
• History of anaphylaxis following any biologic therapy.
• Participant received tezepelumab or other TSLP antibody priorly.
• Participant received bronchial thermoplasty within 12 months.